Published: 2 September 2015
Author(s): Rita Banzi, Chiara Gerardi, Vittorio Bertele', Silvio Garattini
Section: Original Article
This paper examines conditional approvals that allow the marketing of medicines with unsettled benefit–risk profiles in the European Union.